

Original Article**The Effect of Simultaneous Administration of Zinc Sulfate and Ferrous Sulfate in the Treatment of Anemic Pregnant Women***A. Mahmoudian MD*, M. Khademloo MD*****ABSTRACT**

Background: Iron deficiency and its resulting anemia is a common problem among Iranian pregnant women. In spite of iron supplementation program, yet, this problem has not resolved in many parts of the country. Zinc deficiency also is very common in Iran. This study evaluated the efficiency of concomitant zinc and iron therapy in the treatment of anemic pregnant Iranian women.

Methods: A total of 118 anemic women were registered in this randomized controlled trial. Both groups received 100 mg elemental iron daily. The intervention group received an additional dose of 15mg zinc every day for a period of 12 weeks while the control group received placebo. Serum hemoglobin was measured at the beginig of study, after 12 weeks of treatment and at the end of 8 weeks follow-up. Collected data were analyzed with %95 significance level by ANOVA test for comparing baseline characteristics in the two groups and t-test was applied to assess hemoglobin changes in the intervention group.

Results: After 12 weeks of therapy, desirable response was obtained in 78.35% and 93.1% (CI=95%) of anemic women in control and intervention group, respectively which showed a significant difference (P<0.05). Increase in serum hemoglobin just after 12 weeks of treatment was 2.22 ± 0.77 and 1.5 ± 0.66 (gr/dl) in intervention and control group respectively, (P<0.001). Serum hemoglobin differences in the two groups 8 weeks later (step2) when iron alone was administered to both groups were 2.24 ± 0.77 and 1.49 ± 0.66 (gr/dl) respectively . (P<001)

Conclusion: this study clearly demonstrated the efficacy of this inexpensive and simple intervention in the treatment of anemia and prevention of its recurrence in anemic pregnant women.

Key words: Anemia, Pregnant women, Supplement, Isfahan, Zinc sulfate, Ferrous sulfate

JRMS 2005; 10(4): 205-209

Iron deficiency anemia is recognized as the most prevalent nutritional problem in the world¹. More than 90% of anemic patients are living in developing countries. In Iran, the prevalence of anemia is relatively high. 10.5% of high school female students in Lar city², 7.2% of 1-5 year old children in Kerman city³ and 23.8% of women in reproductive ages in Ilam city⁴ are suffering from anemia.

The prevalence of low ferritin level and low transferin saturation are more than anemia^{3,4}. Iron requirement in pregnant women is more than in other women. Iron deficiency anemia is

common in pregnant women in India (56.6%), Iran (17.4%), Peru (50%) compared to Germany (2.2%)⁵⁻⁸.

Anemic pregnant women are at risk of fatigue, reduction of mental and physical activity, high mortality rate, premature labor and low birth weight of their newborns^{9, 10}.

Despite policies advocating iron supplementation for high risk groups such as breast-fed children, pregnant and lactating women, few effective interventions have so far been identified¹¹.

* Associate Professor, Department of Social Medicine, Isfahan University of Medical Sciences and Health Services, Isfahan, Iran

** Associate Professor, Department of Social Medicine, Sari University of Medical Sciences and Health Services, Sari, Iran

Correspondence to: Dr. Ahmad Mahmoudian, Department of Social Medicine, Faculty of Medicine, Isfahan University of Medical Sciences and Health Services, Isfahan, Iran. E-mail: a_mahmoudian@med.mui.ac.ir

Two basic causes of this issue are: multiple micronutrient deficiencies and insufficient drug use

Imani's study in Zahedan showed that only 18% of mothers used iron supplements for their children¹² and study of Kalantary in Isfahan indicated that anemia persisted in 70% of pregnant women in spite of regular iron use¹³. Malekafzali et al evaluated the efficacy of iron supplementation in Varamin but there were not any increase in ferritin level¹⁴.

Now researchers have paid more attention to zinc¹⁵. This element has a basic role in human metabolic activity, cellular mitosis, protein synthesis and the enzymatic processes¹⁶. It is also a component of enzyme "Aminolevulinate Dehydratase" which changes ALA to protoporphyrinogen in the heme synthesis pathway¹⁷.

In 63% of pregnant women and 70% of lactating women in Isfahan, serum zinc level was below 60 µg/dl^{18, 19}.

In this study we tried to find whether simultaneous administration of zinc and iron can raise hemoglobin level higher than what is achieved with iron supplementation per se.

Subjects and Methods

In a double blind placebo controlled clinical trial, 130 anemic pregnant women from primary health care centers in urban and rural areas of Isfahan were selected. A hemoglobin level less than 11g/dl was defined as anemia²⁰. Blood samples were tested by cyanomethemoglobin method. Laboratory tests were done at the end of the first trimester of pregnancy after history-taking and physical examination by a physician. Health center physicians observed blood exam results. They also sought past history of anemia and if positive, they evaluated clinical reasons for causes of anemia other than iron deficiency. Anemic pregnant women with evidence of iron deficiency anemia were referred to family health technicians.

Health centers were divided in two groups randomly by the health staff supervisor. (A and B) Drugs and placebo in similar shape were put in coded boxes (A and B) and delivered to family health care centers. Women who

accepted to take zinc sulfate entered the research.

Health workers were informed of zinc importance. Patient education and data collection were carried out by trained health care staff. They instructed mothers in health care and correct way of drug use.

Group 1 received daily supplements of 100 mg of iron (as ferrous sulfate) and placebo similar to zinc sulfate pills. Group 2 received the same amount of iron along with 15 mg of zinc (as zinc sulfate) for 3 months. This regimen was begun between 16th and 20th weeks of pregnancy. After 3 months of treatment, both groups received 50 mg iron alone for two months thereafter.

They referred to health care centers once or twice every month for prenatal care. Health workers monitored their drug compliance, and recorded information in the forms. In case of failure to use the drugs regularly or if a complication occurred, the subject was excluded from the study. After 3 and 5 months intervention, hemoglobin concentration was measured, and information was recorded.

Data were entered into SPSS software and were analyzed. Independent t-test was used to compare baseline characteristics in the two groups with 95% significance level and repeated measurement. ANOVA was used to compare hemoglobin changes in the two groups by intervention type.

Results

From the total 118 pregnant woman who completed the first step, 115 could finish step 2 of the study.

Selected characteristics of anemic women are presented in Table 1. Past history of pregnancy, abortion and anemia are presented in table 2. At the beginning of intervention, there were no significant differences between the two groups ($p > 0.05$).

After 12 weeks of therapy, desirable response was observed in 78.3% and 93.1% of anemic women in the control and intervention groups, respectively which demonstrated significant differences. ($X^2 = 5.8$, $df = 1$, $P < 0.05$).

Changes in hemoglobin concentration during the course of treatment are presented in Table 3. As shown, there are significant differences in hemoglobin concentration according

to the type of treatment in both steps. ($p < 0.001$)

Table 1. Baseline characteristics of anemic pregnant women

| Charecteristics | group 1 (n=58) | Group 2 (n=60) | Mean difference | 95% CI |
|--------------------------|---------------------------------|---------------------------------|-----------------|---------------|
| | (Mean \pm Standard deviation) | (Mean \pm Standard deviation) | | |
| Weight (Kg) | 65.43 \pm 9.18 | 63.6 \pm 11.07 | 1.82 | 1.89 – 5.53 |
| Height (cm) | 158.88 \pm 6.07 | 159.08 \pm 6.03 | 0.20 | 2 – 2.41 |
| BMI (kg/m ²) | 25.26 \pm 3.91 | 25.82 \pm 4.00 | 0.14 | 0.88 – 1.99 |
| Hemoglobin (kg/dl) | 10.44 \pm 0.2 | 10.46 \pm 0.2 | 0.77 | 0.100 – 0.105 |

Table 2. Past history of pregnancy, abortion and anemia

| Charecteristics | Group 1 (n=58) | Group 2 (n=60) | Mean diffrence | 95% CI |
|-------------------------|----------------|----------------|----------------|--------------|
| Pariety | 0.16 | 0.57 - 0.24 | | |
| 1 | %19.0 | %25.3 | -- | -- |
| 2 | %39.6 | %36.7 | -- | -- |
| 3 | %24.1 | %19.7 | -- | -- |
| >3 | %15.3 | %18.3 | -- | -- |
| Abortion (Past history) | %6.9 | %8.3 | 0.01 | 0.11 – 0.07 |
| Anemia (Past history) | %8.6 | %8.3 | 0.0 | 0.100- 0.105 |

Table 3. Hemoglobin concentration before and after the treatment

| Group | Hemoglobin | | |
|-------------|------------------|-------------------------|-------------------------|
| | Before treatment | After 3 months (step 1) | After 5 months (step 2) |
| Iron | 10.44 \pm 0.24 | 11.94 \pm 0.90 | 11.93 \pm 0.94 |
| Zinc + iron | 10.46 \pm 0.24 | 12.68 \pm 1.01 | 12.70 \pm 1.01 |

repeated measure ANOVA : $P < 0.001$

Discussion

In the present study, the administration of zinc besides iron in the treatment of anemic pregnant woman affected hematological response in 12 weeks of treatment and persisted 8 weeks after withdrawal of zinc sulfate. The same finding was observed in Nishiyama's study ²¹. In contrast, no benefit resulted from co-administration of zinc and iron to the same group in Zavaltá's study in Peru ²². Maybe, Such differences are related to the zinc status in the Peruvian people's diet compared to other nations such as Iranian people.

In our study, 93.1% of zinc plus iron group and 78.3% of iron plus placebo group responded to treatment as hemoglobin increased to more than 11 g/dl. It appears that multiple micronutrient deficiency is the most important cause of insufficient anemia treatment response.

Kolesteren compared the use of vitamin A and iron versus iron alone in the treatment of anemia and Ravanshad added vitamin C to iron ^{23, 24}. Both of those studies found beneficial effects of co-administration.

There are other data and experiences that showed zinc administration relieves symptoms

such as fatigue, anorexia, hair loss and nail dystrophy in many patients.

Zinc content of soil is depleted in many areas of the world. In addition, high zinc foods such as meat, egg, milk and etc are used less than recommended, and incorrect processing of bread decreases zinc absorption. It is also proved that oral iron can decrease zinc absorption and serum zinc level ²⁵.

In conclusion, we suggest that more attention should be paid to zinc deficiency and zinc supplementation in pregnant women.

Moreover, people should be educated on nutrition and dietary sources of zinc through health programs on mass media.

We also recommend more studies in this field to highlight the advantages of zinc supplementation in health care programs.

References

1. World Health Organization . *Turning the tide of malnutrition: responding to the challenge of the 21th century*. Geneva: WHO 2000 (WHO/NHD.007)
2. Vizshfar F, Zarif- sanai N. *Iron deficiency anemia screening in high school students of Lar. The First Congress of Ambulatory Medicine in Iran, Shiraz- Iran 1998; 137*
3. Heidarnia A, Dabiri Sh, Farahmandinia Z, Mohamadalizade S. *Prevalence of iron deficiency anemia in 1-5 yrs children of Kerman. Journal of Kerman University of Medical Sciences 1998; (4): 214-21*
4. Vahidnia A. *Prevalence of iron deficiency anemia in women of reproductive age of Ilam. The First Congress of Ambulatory Medicine in Iran, Shiraz- Iran 1998; 136*
5. Abel R, Ragaratim J, Gnanasekaran VJ, Janyaraman P *Prevalence of anemia and iron deficiency in three trimesters in Rural Velore District , Siuth India. Trop DOCT. 2001, 31(2):86-9*
6. Saghzade A. *Prevalence of iron deficiency anemia in pregnant women of Ahvaz. Theses of nutritional science, Shahid Beheshti University of Medical Sciences, Tehran, 1993*
7. Zavalta N, Berlanga R, Lonnerdal B, Brown KH. *Prevalence and determinants of iron deficiency anemia in representative sample of pregnant Women in lima, Peru. Washington DC: Pan American Health Organization, 1993*
8. Wagener IE, Bergmann RI, Kamtsiuris P, Eisenreich B, Andres B, Eckert C, et al. *Prevalence and risk factors of iron deficiency in young mothers. Gesundheitswesen. 2000; 62(3): 176-8*
9. World Health Organization, *Nutrition , health and development, a global agenda for combating malnutrition. Geneva, WHO, 2000 (WHO/NHO/OO.6)*
10. Murphy JF, O Riordan J, Newcombe RG, Coles EC, Pearson IF. *Relation of haemoglobin levels in first and second trimesters to outcome of pregnancy. Lancet 1986; 3,1(8488): 992-5.*
11. Marandi A, Azizi F, Larijani H. *Health in Islamic Republic of Iran. Ministry of Health and Medical Education of Iran – YONICE, Tehran 1998*
12. Imani M, Rakhshani F, Ansarimoghdam A. *Behavior of Zahedanian mothers for use of iron (drop) to their children. First Congress of General Health and Prevention, Kermanshah University of Medical Sciences 2001, P:232*
13. Kalantari N, Karimabade N, Samadnian F, Jamshidian M. *Evaluation of iron supplementation program for pregnant women in health care centers of Isfahan. Research plan, Nutrition and Food Research Institute of Iran 2001*
14. Malekafzali H, Salamchi P. *The effect of different doses of iron to hemoglobin level in second half of pregnancy in Varamin. Theses of nursing, Isfahn University of Medical Sciences 1995*
15. Simmmer K , Iort- phil, James C , Thompson RPH. *A double blind trial of zinc supplements in pregnancy. Eur J Clin Nutr 1991; 45: 139-44*
16. Garrow JS, James WPT, Ralh A. *Human nutrition and Dietetics.UAS, Churchill-Livingstine 2000; P 192-96*
17. Murray RK, Pophyrins and bile pigments. in Murray RK, Granner DK, Mayes PA, Rodwell VW. *Harper's Biochemistry, 25th ed, McGrawhill 2000; 359-374*
18. Mahmoudian A, Ghadirif , Heidarzade A. *Serum zinc level in lactaing women of Isfahan. Reserch in Medical Sciences 2002; 7(1): 33-37*
19. Shahshahan, Heidarzade A. *Serum zinc level in pregnant women of Isfahan. First Congress of General Health and Prevention, Kermanshah University of Medical Sciences 2001*
20. Cunnighan FG, Gant nf, Leveno KJ, Gilstrap LC, Hauth JC, Wenstrom KD *Williams obstetrics and gynecology, USA, McGrawhill 2001; 178*

21. Nishiyama S, Kiwaki K, Miyazaki Y, Hasuda T. Zinc and IGF-I concentrations in pregnant Woman with anemia before and after supplementation with iron and or zinc. *J Am Coll Nutr* 1999; 18(3) :261-7
22. Zavaleta N, Caulfield Le, Garcia T. Changes in iron status during pregnancy in Peruvian women receiving prenatal iron and folic acid supplements with or without zinc. *Am J Clin Nutr* 2000; 71(4):956-61
23. Kolsteren P, Rahman SR, Hilderbrand K. Treatment for iron deficiency anaemia with a combined supplementation of iron, vitamin A and zinc in women of Dinajpur, Bangladesh. *Eur J Clin Nutr* 1999; 53(2):102-6
24. Ravanshad S, Alighanbari M, Zakerian M, Zeighami B. Effect of vitamin C and iron in hematological deficits in middle aged women. *J Am Coll Nutr* 1998; 17(3): 291-5
25. O'Brien K , Zavaleta N, Caulfield LE , Wen J, Abrams SA. Prenatal iron supplements impair zinc absorption in pregnant peruvian Women. *J Nutr* 2000; 190(9): 2251-5